Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 46

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 46
---
 for failure to deliver any shares of Common Stock issuable upon exercise.
If at the time of exercise of the January 2025 Common Warrants, there is no effective registration statement registering the shares of
the Common Stock underlying the January 2025 Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms.

If we issue options, convertible
securities, warrants, shares, or similar securities to holders of Common Stock, each holder of December 2024 Common Warrants and January
2025 Common Warrants have the right to acquire the same as if the holder had exercised its December 2024 Common Warrants or January 2025
Common Warrants. The holders of December 2024 Common Warrants and January 2025 Common Warrants are entitled to receive any dividends paid
or distributions made to our holders of Common Stock on an “as if converted” basis.

The December 2024 Common
Warrants and January 2025 Common Warrants prohibit us from entering into specified fundamental transactions unless the successor entity
assumes all of our obligations under the December 2024 Common Warrants and January 2025 Common Warrants agreements before the transaction
is completed. Upon specified corporate events, a holder of December 2024 Common Warrants and January 2025 Common Warrants will thereafter
have the right to receive upon an exercise such shares, securities, cash, assets or any other property whatsoever which the holder would
have been entitled to receive upon the happening of the applicable corporate event had the December 2024 Common Warrants and January 2025
Common Warrants been exercised immediately prior to the applicable corporate event. Upon the consummation of any Fundamental Transaction,
the Company shall exchange the December 2024 Common Warrants and January 2025 Common Warrants for consideration equal to the Black Scholes
Value of such portion of the December 2024 Common Warrants and January 2025 Common Warrants subject to exchange (collectively, the “Aggregate
Black Scholes Value”) in the form of, at the Company’s election (such election to pay in cash or by delivery of the Rights
(as defined below), a “Consideration Election”), either (I) rights (with a beneficial ownership limitation, mutatis mutandis)
(the “Rights”), convertible in whole, or in part, at any time, without the requirement to pay any additional consideration,
at the option of the Holder, into such Corporate Event Consideration applicable to such Fundamental Transaction equal in